Trial Profile
A Phase 1/2 Clinical Study to Evaluate the Optimal Dose and the Protective Effect of CMV-MVA Triplex Vaccine in Pediatric Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs MVA CMV (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- 25 Sep 2023 Planned End Date changed from 31 Aug 2023 to 11 Nov 2024.
- 25 Sep 2023 Planned primary completion date changed from 31 Aug 2023 to 11 Nov 2024.
- 15 Jun 2023 According to a Helocyte media release, the company announced that the National Cancer Institute has awarded a 3.22 million dollars grant to City of Hope for clinical studies of Triplex, a cytomegalovirus vaccine being developed by Helocyte and City of Hope.